Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00031 | Brentuximab vedotin | 914088-09-8 |
| Brentuximab vedotin is an antibody-drug conjungate (ADC) used for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin acts through targeting tumor cells with CD30 antigen expressed in. | Inquiry | |
| BADC-01595 | Datopotamab deruxtecan | 2238831-60-0 |
| Datopotamab deruxtecan is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. | Inquiry | |
| BADC-01593 | Cantuzumab mertansine | 400010-39-1 |
| Cantuzumab mertansine is an immunoconjugate of the potent maytansine derivative (DM1) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has the potential for the treatment of advanced solid tumors. | Inquiry | |
| BADC-00023 | Trastuzumab emtansine | 1018448-65-1 |
| Trastuzumab emtansine is an antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surface surfaces. Upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers. | Inquiry | |
| BADC-01592 | Gemtuzumab ozogamicin | 220578-59-6 |
| Gemtuzumab ozogamicin is an ADC consisting of a derivative of calicheamicin linked to a humanized monoclonal IgG4 antibody directed against CD33. Gemtuzumab ozogamicin has been approved for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid leukemia (AML). | Inquiry | |
| BADC-01598 | Anetumab-MMAE | |
| Anetumab-MMAE is an antibody-drug conjugate consisting of an anti-MSLN monoclonal antibody and monomethyl auristatin E (MMAE). MMAE is an antimitotic agent that inhibits tubulin polymerization. | Inquiry | |
| BADC-01599 | Anetumab ravtansine | 1375258-01-7 |
| Anetumab ravtansine is an antibody-drug conjugate consisting of an anti-MSLN monoclonal antibody and the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential for the treatment of patients with mesothelin-expressing tumors. | Inquiry | |
| BADC-01600 | Sirtratumab vedotin | 1824663-83-3 |
| Sirtratumab vedotin is an antibody-drug conjugate consisting of a SLITRK6-specific human antibody conjugated to MMAE via a protease-cleavable linker. Sirtratumab vedotin has the potential for the treatment of advanced urothelial cancer. | Inquiry | |
| BADC-01601 | Tusamitamab ravtansine | 2254086-60-5 |
| Tusamitamab ravtansine is an antibody-drug conjugate consisting of an anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) antibody conjugated to the potent cytotoxic antitubulin DM4. It has been used in the research of solid tumor treatment. | Inquiry | |
| BADC-01594 | Labetuzumab govitecan | 1469876-18-3 |
| Labetuzumab govitecan is a conjugate of a humanized antibody to CEACAM5, coupled site-specifically to the active metabolite of irinotecan, SN-38 (7.6 moles SN-38/IgG), using a proprietary linker. | Inquiry | |
| BADC-01596 | Enfortumab vedotin-ejfv | 1346452-25-2 |
| Enfortumab vedotin-ejfv is a first-in-class monoclonal antibody drug conjugate that binds Nectin-4, a protein expressed on bladder cancer cells, and delivers the tubulin toxin, monomethyl auristatin E, into the cell causing cell death. Enfortumab vedotin-ejfv was approved by FDA for the treatment of locally advanced or metastatic urothelial cancer. | Inquiry | |
| BADC-01597 | Ladiratuzumab vedotin | |
| Ladiratuzumab vedotin is an antibody-drug conjugate consisting of a humanized anti-LIV-1 IgG1 conjugated with monomethyl auristatin E (MMAE). Ladiratuzumab vedotin has the potential for the treatment of metastatic triple-negative breast cancer. | Inquiry | |
| BADC-01602 | Trastuzumab deruxtecan | 1826843-81-5 |
| Trastuzumab deruxtecan is an antibody-drug conjugate consisting of humanized anti-HER2 antibody and a topoisomerase I inhibitor payload. Trastuzumab deruxtecan has been used in the research of HER2 expressing solid tumor therapy. | Inquiry | |
| BADC-01603 | Sacituzumab govitecan | 1491917-83-9 |
| Sacituzumab govitecan is an antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer. | Inquiry | |
| BADC-01604 | Disitamab vedotin | 2136633-23-1 |
| Disitamab vedotin is an antibody-drug conjugate consisting of the novel humanized anti-HER2 antibody (hertuzumab) conjugated to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin has been used in the research of HER2‑positive metastatic breast cancer therapy. | Inquiry | |
| BADC-01605 | Telisotuzumab vedotin | 1714088-51-3 |
| Telisotuzumab vedotin is a c-Met-targeted antibody and MMAE drug conjugate. Telisotuzumab vedotin has the potential for advanced non-small cell lung cancer treatment. | Inquiry | |
| BADC-01606 | Polatuzumab vedotin | 1313206-42-6 |
| Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. Polatuzumab vedotin has been approved for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL). | Inquiry | |
| BADC-01607 | Belantamab mafodotin | 2050232-20-5 |
| Belantamab mafodotin is an antibody-drug conjugate consisting of an antibody targeting B-cell maturation antigen (BCMA) conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). Belantamab mafodotin has been approved for the treatment of multiple myeloma. | Inquiry | |
| BADC-01608 | Loncastuximab tesirine | 1879918-31-6 |
| Loncastuximab tesirine is an anti-CD19 antibody-drug conjugate. Loncastuximab tesirine has been used in the research of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). | Inquiry | |
| BADC-01609 | Patritumab deruxtecan | 2227102-46-5 |
| Patritumab deruxtecan is an antibody-drug conjugate consisting of a human anti-HER3 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. | Inquiry |
